Appendix 1 Procedure for the development of locally approved Shared Care Agreements (SCAs)

Lothian Formulary Committee (FC) makes a decision on the appropriate place in therapy of a new medicine following national and local recommendations. The medicine is considered suitable for specialist initiation and therefore may be continued in a primary care setting, and is flagged as SI on the formulary website. Shared care agreements (SCAs) provide additional support for GPs and primary care non-medical prescribers, however, it is not Development of SCA using agreed template [Appendix 2] by health professionals necessary to have a locally approved document in place in order to share care. Specialist Clinicians Develop locally approved shared care agreement documents for those complex treatments routinely used in a specialist setting, for which GPs may For the purposes of this procedure a require additional support and guidance. Relevant people should be involved in the medicine is considered to be eligible for a development of the SCA, in particular GPs. shared care agreement if it can be initiated in General Practitioners and primary care non-medical prescribers Contribute to the secondary care and then prescribed in development of locally approved SCAs in partnership with secondary care colleagues. primary care and meets the following Clinical Directors, Associate Divisional Medical Director, Clinical Management Team, criteria: **Director of Operations, Primary Care Managers and Clinical Directors** prescribed for a potentially serious Consider resource implications of implementation of SCAs in primary care. condition Hospital Clinical Pharmacists Contribute to the development of SCAs in collaboration complex [intended use likely to be with the prescribing clinicians. outwith the clinical experience of a Coordinate the revision of existing SCAs in association with the specialist team. GP1 Primary Care Pharmacists Support GPPC and the Medicines Management Team in relatively high adverse effect managing the processes involved in the development, submission, approval and review profile of SCAs. may require specific monitoring and dose titration new, or rarely prescribed SCA is submitted to the General Practice Prescribing Committee (GPPC) for approval Approved SCA added to Formulary website

If it is considered that a SCA is no longer required, it can be proposed to be withdrawn (see also Appendix 3) - this is agreed by the GPPC.

Procedure for the shared care of medicines, Version 3.0 Document owner: Lead Pharmacist, Medicines Management Team Authorised by: ADTC 27 August 2021 Review Date: August 2024